An announcement from West Pharmaceutical Services ( (WST) ) is now available.
West Pharmaceutical Services reported a slight decline in third-quarter 2024 net sales to $746.9 million and a drop in adjusted earnings per share to $1.85 from $2.16 last year. Despite these declines, the company raised its full-year sales and EPS guidance due to favorable currency movements. West’s proprietary products segment saw a minor sales decline, while contract-manufactured products experienced slight growth. The company also announced a dividend increase, continuing its long-standing annual dividend growth tradition.
For a thorough assessment of WST stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
